- Home
- LPA vs ATYR Comparison
LPA vs ATYR Comparison
Compare LPA & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPA
- ATYR
- Stock Information
- Founded
- LPA 2013
- ATYR 2005
- Country
- LPA United States
- ATYR United States
- Employees
- LPA N/A
- ATYR N/A
- Industry
- LPA
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LPA
- ATYR Health Care
- Exchange
- LPA Nasdaq
- ATYR Nasdaq
- Market Cap
- LPA 310.7M
- ATYR 330.7M
- IPO Year
- LPA N/A
- ATYR 2015
- Fundamental
- Price
- LPA $8.98
- ATYR $3.97
- Analyst Decision
- LPA
- ATYR Strong Buy
- Analyst Count
- LPA 0
- ATYR 6
- Target Price
- LPA N/A
- ATYR $18.60
- AVG Volume (30 Days)
- LPA 6.1K
- ATYR 2.0M
- Earning Date
- LPA 03-25-2025
- ATYR 03-13-2025
- Dividend Yield
- LPA N/A
- ATYR N/A
- EPS Growth
- LPA N/A
- ATYR N/A
- EPS
- LPA N/A
- ATYR N/A
- Revenue
- LPA $44,311,428.00
- ATYR $235,000.00
- Revenue This Year
- LPA N/A
- ATYR $1,387.23
- Revenue Next Year
- LPA N/A
- ATYR $873.22
- P/E Ratio
- LPA N/A
- ATYR N/A
- Revenue Growth
- LPA 22.46
- ATYR N/A
- 52 Week Low
- LPA $6.00
- ATYR $1.42
- 52 Week High
- LPA $525.00
- ATYR $4.66
- Technical
- Relative Strength Index (RSI)
- LPA N/A
- ATYR 56.81
- Support Level
- LPA N/A
- ATYR $2.98
- Resistance Level
- LPA N/A
- ATYR $3.73
- Average True Range (ATR)
- LPA 0.00
- ATYR 0.40
- MACD
- LPA 0.00
- ATYR 0.04
- Stochastic Oscillator
- LPA 0.00
- ATYR 80.32
About LPA Logistic Properties of the Americas
Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns and manages a diversified portfolio of warehouse logistics assets in Central America and the South America. It focuses on modern Class A logistics real estate in high growth and high barrier-to-entry markets that are undersupplied and have low penetration rates.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.